Aclaris Therapeutics, Inc.
NASDAQAclaris Therapeutics reports Q1 results tomorrow morning with a setup that cuts several ways at once: a fresh analyst initiation, a put/call ratio at its highest level in a year, and short sellers holding a meaningful but stable position ahead of what has historically been a volatile print. The most striking development this week is the sudden surge in options-implied caution. The…
Snapshot as of 3 Jun 2026
Aclaris Therapeutics reports Q1 results tomorrow morning with a setup that cuts several ways at once: a fresh analyst initiation, a put/call ratio at its highest level in a year, and short sellers holding a meaningful…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ACRS — free to start on ORTEX.
Sign up for free →Open ACRS on ORTEX